NEW YORK (June 27, 2019) — Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that it has entered into a sponsored research agreement with the George Washington University (GW) to explore the potential use of Aprepitant for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients.
Erlotinib is a drug that is used to combat various cancers and has been known to cause varying degrees of skin rashes, lesions, hair loss and nail changes to patients. These side-effects can impact the patient's quality of life and even cause treatment interruption, jeopardizing the overall success of the treatment. The research agreement intends to explore whether other chronic conditions that also display dermatitis may benefit from this novel therapeutic approach. Overseeing this collaboration will be William B. Weglicki, MD, professor of biochemistry and molecular medicine and professor of medicine at the GW School of Medicine and Health Sciences.
"Hoth is pleased to partner with GW as we research treatments to improve the quality of life of patients that are undergoing lifesaving treatments," stated Robb Knie, CEO of Hoth Therapeutics, Inc. "We couldn't ask for a better partner on the Aprepitant project. We have already begun collaborating with Dr. Weglicki, and his team, and their expertise is immediately evident. We look forward to working with such a talented group and will announce our first study at GW in the coming weeks."
Weglicki commented, "We look forward to investigating the efficacy of this promising therapy that targets the side effects of cutaneous toxicity due to some anticancer drugs. Our investigators at GW anticipate productive future collaborations with Hoth's innovative scientific research team. These synergistic efforts will concentrate on treatment of dermatological side effects, some of which may be so severe that many patients may choose to discontinue potentially life-prolonging cancer drug therapy."
This release is posted courtesy of Hoth Therapeutics, Inc.